Engineered immune cells take on Hard-to-Treat cancers
NCT ID NCT07181720
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 27 times
Summary
This early-stage study tests a new treatment called CD70-targeted CAR-T cells in people with advanced solid tumors, including kidney, lung, and ovarian cancers. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells that have a specific marker (CD70). The main goals are to check safety and find the best dose, while also seeing if it can control tumor growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The 901 Hospital of Joint Logistics Support Force of People Liberation Army
RECRUITINGHefei, Anhui, 230031, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.